Targeted treatments in advanced renal cell carcinoma: focus on axitinib
Elena Verzoni, Paolo Grassi, Isabella Testa, Roberto Iacovelli, Pamela Biondani, Enrico Garanzini , Filippo De Braud, Giuseppe ProcopioDepartment of Medical Oncology 1, Fondazione IRCCS Istituto Nazionale Tumori, Milan, ItalyAbstract: Antiangiogenesis options have evolved rapidly in the last few yea...
Saved in:
Main Authors: | Verzoni E (Author), Grassi P (Author), Testa I (Author), Iacovelli R (Author), Biondani P (Author), Garanzini E (Author), De Braud F (Author), Procopio G (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2014-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy
by: Grassi P, et al.
Published: (2016) -
Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy
by: Bellesoeur A, et al.
Published: (2017) -
A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma
by: Tiako Meyo M, et al.
Published: (2022) -
A Cost-Effectiveness Analysis: First-Line Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma
by: Peiyao Lu, et al.
Published: (2020) -
Cost-effectiveness comparison of cabozantinib with everolimus, axitinib, and nivolumab in the treatment of advanced renal cell carcinoma following the failure of prior therapy in England
by: Meng J, et al.
Published: (2018)